 LAS VEGAS, June 23, 2021 PRNewswire -- JanOne Inc. Nasdaq: JAN, a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that its clinical packaging partner Xerimis has received the bottled clinical batch of JAN101 for the upcoming Phase 2b trial for treating Peripheral Artery Disease PAD and is readying the supply for labeling and distribution to clinical sites throughout the U.S. We are pleased to report that our clinical supply of JAN101 is now ready for near-term release to our expected clinical trial sites in the upcoming Phase 2 clinical trial, said Tony Isaac, President and Chief Executive Officer of JanOne. We are fully prepared and look forward to FDA approval of our new protocol. 